Combined Zidovudine and Interferon-α 2a Therapy in Children with Acquired Immune Deficiency Syndrome

Abstract

A study was carried out in five children with acquired immune deficiency syndrome to assess the effect of combined zidovudine/interferon-α_2a therapy with that of zidovudine given alone on immunological profiles and plasma zidovudine concentrations. Immunoglobulins A, G and M, total and absolute CD4 lymphocyte counts, and p24 antigen concentrations did not differ significantly when children were treated with 300 mg/m² zidovudine given orally once every 12 h, or with 150 mg/m² zidovudine plus 1.5 or 3 MIU interferon-α_2a given intramuscularly three times weekly. Peak plasma zidovudine concentrations were significantly (P < 0.05) lower when combined treatment with 150 mg/m² zidovudine/1.5 MIU interferon-α_2a was administered compared with 300 mg/m² zidovudine alone, or combined 150 mg/m² zidovudine/3 MIU interferon-α_2a The results suggest that combination zidovudine/interferon-α_2a therapy may be more efficacious than zidovudine alone and that the normal zidovudine dose may be reduced if interferon-α_2a is given in addition, thus reducing the side-effects associated with zidovudine.

Keywords

Zidovudine Interferon-α Combination therapy Acquired immune deficiency syndrome Children

Get full access to this article

View all access options for this article.

References

Fischl

Richman

Grieco

: The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med 1987; 317: 185–191.

Dournon

Matheron

Rozenbaun

: Effects of zidovudine in 365 consecutive patients with AIDS or AIDS-related complex. Lancet 1988; ii: 1297–1302.

Larder

Darby

Richman

: HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989; 243: 1731–1734.

Hartsborn

Vogt

Chou

: Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha a interferon. Antimicrob Agents Chemother 1987; 31: 168–172.

Mitsuya

Weinhold

Furman

: 3‘-Azido-3’-deoxythymidine: an antiviral agent that inhibits the infectivity and cytopathic effect of human T lymphotropic virus type III/lymphadenopathy-associated virus in vitro . Proc Natl Acad Sci USA 1985; 82: 7096–7100.

Sen

: Mechanism of interferon action: progress towards its understanding. Prog Nucleic Acid Res Mol Biol 1982; 27: 105–156.

Kovacs

Deyton

Davey

: Combined zidovudine and interferon alpha therapy in patients with Kaposi sarcoma and the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1989; 111: 280–287.

Krown

Gold

Niedzwiecki

: Interferon alpha with zidovudine: safety, tolerance and clinical and virological effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1990; 112: 812–821.

Centres Disease Control : Classification system for human immunodeficiency virus infection in children under 13 years of age. MMWR 1987; 32: 225–230, 235.